Ophthotech has entered into an IPO financing round in the hope of raising up to $85 million.
After assembling a whopping $175 million financing deal this spring, Ophthotech has filed paperwork with the SEC to secure up to $85 million more in an IPO financing round.
Ophthotech has hit the IPO financing trail after announcing plans to advance its lead therapy Fovista into Phase III clinical development for wet age-related macular degeneration by the end of 2013.
Upbeat results from a Phase IIb study showed that a treatment with a combination of the compound, an inhibitor of platelet-derived growth factor, and Roche's anti-VEGF therapy Lucentis, outperformed Lucentis alone for treating the leading cause of blindness in people aged 55 and older.
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity